Hypoxic tumor microenvironment and cancer cell differentiation - PubMed (original) (raw)
Review
Hypoxic tumor microenvironment and cancer cell differentiation
Yuri Kim et al. Curr Mol Med. 2009 May.
Abstract
Hypoxia or oxygen deficiency is a salient feature of solid tumors. Hypoxic tumors are often resistant to conventional cancer therapies, and tumor hypoxia correlates with advanced stages of malignancy. Hypoxic tumors appear to be poorly differentiated. Increasing evidence suggests that hypoxia has the potential to inhibit tumor cell differentiation and thus plays a direct role in the maintenance of cancer stem cells. Studies have also shown that hypoxia blocks differentiation of mesenchymal stem/progenitor cells, a potential source of tumor-associated stromal cells. It is therefore likely that hypoxia may have a profound impact on the evolution of the tumor stromal microenvironment. These observations have led to the emergence of a novel paradigm for a role of hypoxia in facilitating tumor progression. Hypoxia may help create a microenvironment enriched in poorly differentiated tumor cells and undifferentiated stromal cells. Such an undifferentiated hypoxic microenvironment may provide essential cellular interactions and environmental signals for the preferential maintenance of cancer stem cells. This hypothesis suggests that effectively targeting hypoxic cancer stem cells is a key to successful tumor control.
Figures
Fig. 1. Tumor hypoxia and cancer stem cell niches
Because hypoxia inhibits cellular differentiation, cancer stem cells will be preferentially located in hypoxic regions where increased numbers of immature stromal cells are also expected. The self-renewal and maintenance of cancer stem cells will be improved via hypoxia-induced signal transduction, as well as direct and indirect interactions with immature stromal cells. In contrast, the non-hypoxic tumor microenvironment will likely be populated with differentiated stromal cells. Cancer stem cells will be subjected to increasing stresses for differentiation.
References
- Vaupel P, Kelleher DK, Hockel M. Semin Oncol. 2001;28:29–35. - PubMed
- Becker A, Stadler P, Lavey RS, Hansgen G, Kuhnt T, Lautenschlager C, Feldmann HJ, Molls M, Dunst J. Int J Radiat Oncol Biol Phys. 2000;46:459–466. - PubMed
- Vaupel P, Mayer A, Briest S, Hockel M. Cancer Res. 2003;63:7634–7637. - PubMed
- Collingridge DR, Piepmeier JM, Rockwell S, Knisely JP. Radiother Oncol. 1999;53:127–131. - PubMed
- Evans SM, Koch CJ. Cancer Lett. 2003;195:1–16. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K18DK078899/DK/NIDDK NIH HHS/United States
- T32/PHS HHS/United States
- R01 CA125021/CA/NCI NIH HHS/United States
- R01CA125021/CA/NCI NIH HHS/United States
- K18 DK078899/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources